Rapid and sensitive method for determination of piroxicam in human plasma by high-performance liquid chromatography

Máček, Ján; Vácha, J

doi:10.1016/0378-4347(87)80203-7

Cited by 23 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several high-performance liquid chromatography (HPLC) methods have been developed for piroxicam determination in human or rat plasma for pharmacokinetic study (Amanlou et al, 1997;Boudinot et al, 1988;Dixon et al, 1984;Gillilan et al, 1989;Macek et al, 1987;Milligan, 1992;Richardson et al, 1986;Riedel et al, 1983;Saeed et al, 1989). Nevertheless, there is a need to improve these methods in terms of ease of sample handling and analysis time.…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic Profiles of Two Branded Formulations of Piroxicam 20mg in Healthy Korean Volunteers by a Rapid Isocratic HPLC Method

Song¹,

Choi²

2009

JBB

View full text Add to dashboard Cite

The aim of this study was to develop and validate for determination of piroxicam in human plasma by new rapid HPLC method and to compare the relative bioavailability of two branded formulations of piroxicam in healthy Korean volunteers. The analysis running time of piroxicam was just 2 minutes using C 18 column (100 x 4.6 mm, 5 µm) with variable wavelength detector (at 355 nm). This HPLC method was validated by examining the precision and accuracy for inter-and intra-day analysis. A randomized, open-label, single dose, 2-period crossover method was performed in 28 subjects. For analysis of pharmacokinetic properties, the blood samples were drawn at 0, 1, 2, 3, 4, 5, 6, 12, 24, 48, 96 and 168 hours after dosing. The standard curve was linear (R 2 = 0.9999) over the concentration range of 0.1-6 µg/mL. The relative standard deviation (R.S.D.) and accuracy were 0.2-6.1 % and 95.4-104.0 %. After single dose of piroxicam 20 mg, the plasma pharmacokinetic parameters, C max , T max , t 1/2 and AUC t were 2.15 ± 0.25 µg/mL, 2.44 ± 1.15 h, 46.84 ± 8.73 h and 107.42 ± 27.25 µg•h/mL in the test drug. No significant differences were found based on analysis of variance, with mean values and 90% CIs of test/reference ratio for these parameters as follows: C max was 0.9351-1.0377; AUC 0-168 was 0.9510-1.0752. The developed method was successfully applied to bioequivalence study of two branded piroxicam capsules in 28 healthy Korean. The results of pharmacokinetics showed two branded piroxicam 20 mg formulations were bioequivalent, based on the regulatory definition.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic Profiles of Two Branded Formulations of Piroxicam 20mg in Healthy Korean Volunteers by a Rapid Isocratic HPLC Method

Song¹,

Choi²

2009

JBB

View full text Add to dashboard Cite

show abstract

“…As noted in the introduction, the double peak phenomena is reported for piroxicam [4][5][6][7][8][9], ranitidine [10][11][12][13][14][15][16], talinolol [18,19], alprazolam [20], phenazopyridine [21] and many other drugs in humans. Ranitidine double peaks are reportedly caused by multiple site absorption [10,17].…”

Section: Resultsmentioning

confidence: 98%

“…Double peak absorption has been described with several orally administered drugs such as cimetidine [1,2], furosemide [3], piroxicam [4][5][6][7][8][9], ranitidine [10][11][12][13][14][15][16][17], talinolol [18,19], alprazolam [20] and phenazopyridine [21]. Several possible explanations are stated for double peak phenomena; some of the double or multiple peak phenomena can be explained sufficiently by a parallel first order absorption model or a multisegment absorption model.…”

Section: Introductionmentioning

confidence: 99%

A simple pharmacokinetics subroutine for modeling double peak phenomenon

Mirfazaelian¹,

Mahmoudian²

2006

Biopharm. Drug Dispos.

View full text Add to dashboard Cite

Double peak absorption has been described with several orally administered drugs. Numerous reasons have been implicated in causing the double peak. DRUG-KNT--a pharmacokinetic software developed previously for fitting one and two compartment kinetics using the iterative curve stripping method--was modified and a revised subroutine was incorporated to solve double-peak models. This subroutine considers the double peak as two hypothetical doses administered with a time gap. The fitting capability of the presented model was verified using four sets of data showing double peak profiles extracted from the literature (piroxicam, ranitidine, phenazopyridine and talinolol). Visual inspection and statistical diagnostics showed that the present algorithm provided adequate curve fit disregarding the mechanism involved in the emergence of the secondary peaks. Statistical diagnostic parameters (RSS, AIC and R2) generally showed good fitness in the plasma profile prediction by this model. It was concluded that the algorithm presented herein provides adequate predicted curves in cases of the double peak phenomenon.

show abstract

“…Piroxicam concentrations in plasma, blood and buffer solution from equilibrium dialysis were determined by using a specific reverse-phase high-pressure liquid chromatographic method, and 0.2 ml of the sample to be analyzed was mixed with 0.3 m1 of an acetonitrile solution containing Tenoxicam as an internal standard (20 mg/l) (17). The mixture was centrifuged at 3500 rpm for 10 min and 10 m1 of supernatant was injected into a Nucleosil CIS column (12.5 em x 0.4 em, LD.…”

Section: Assaysmentioning

confidence: 99%

Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of Piroxicam in vivo in the rat

Troconiz

Lopez-Bustamante

Fos

1993

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

The influence of decreased albumin concentration on the pharmacokinetic behaviour of Piroxicam was studied in vivo in rats that had undergone plasmapheresis. Reductions of approximately 25% and 50% in the plasma albumin concentration were achieved, the former in rats not given plasma expander, the latter in animals given Ficol-70 as a plasma expander. The unbound fraction of Piroxicam in plasma and the apparent volume of distribution at steady state experienced a statistically significant increase where the albumin concentration was reduced. The average total plasma clearance rose with the increase in fu, between the control (6.3 +/- 2.4 ml/h) and plasmapheretic groups (11.1 +/- 4 ml/h), in accordance with predictions of the 'well-stirred' and 'parallel-tube' models, but no statistically significant differences were found between the two groups, perhaps because of the great interindividual variability associated with this parameter. The total plasma clearance value of the Ficol group (5.4 +/- 2.2 ml/h) was close to that of the control group, despite the high increase in the unbound fraction in plasma. Alterations in the uptake process in the liver due to the high level of induced hypoalbuminemia may have occurred.

show abstract

Rapid and sensitive method for determination of piroxicam in human plasma by high-performance liquid chromatography

Cited by 23 publications

References 7 publications

Pharmacokinetic Profiles of Two Branded Formulations of Piroxicam 20mg in Healthy Korean Volunteers by a Rapid Isocratic HPLC Method

Pharmacokinetic Profiles of Two Branded Formulations of Piroxicam 20mg in Healthy Korean Volunteers by a Rapid Isocratic HPLC Method

A simple pharmacokinetics subroutine for modeling double peak phenomenon

Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of Piroxicam in vivo in the rat

Contact Info

Product

Resources

About